Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.72 |
| ▸ | HDAC3 | O15379 | 16/20 | 0.72 |
| ▸ | HDAC8 | Q9BY41 | 16/20 | 0.72 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.72 |
| ▸ | HDAC4 | P56524 | 14/20 | 0.72 |
| ▸ | HDAC7 | Q8WUI4 | 14/20 | 0.72 |
| ▸ | HDAC10 | Q969S8 | 14/20 | 0.72 |
| ▸ | HDAC11 | Q96DB2 | 14/20 | 0.72 |
| ▸ | HDAC9 | Q9UKV0 | 14/20 | 0.72 |
| ▸ | HDAC5 | Q9UQL6 | 14/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296191 | 1.00 | HDAC1 (0.72) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| SCHEMBL295755 | 0.85 | HDAC1 (0.68) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| SCHEMBL295754 | 0.85 | HDAC1 (0.68) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| SCHEMBL13949983 | 0.85 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| SCHEMBL1077092 | 0.83 | HDAC1 (0.50) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| SCHEMBL300030 | 0.83 | HDAC1 (0.50) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| SCHEMBL296350 | 0.79 | HDAC1 (0.66) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| SCHEMBL296175 | 0.79 | HDAC1 (0.66) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| SCHEMBL28763316 | 0.79 | HDAC1 (0.62) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| SCHEMBL297056 | 0.79 | HDAC1 (0.57) | HDAC1HDAC6HDAC3HDAC8HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969401-B2 | Sulfonylpyrroles | 4SC AG (DE) | 2015-03-03 | — | — | US | claimed |
| EP-1725528-B1 | SULPHONYLPYRROLES AS HDAC INHIBITORS | 4SC AG (DE) | 2013-05-29 | — | — | EP | claimed |
| US-20130079347-A1 | NOVEL SULFONYLPYRROLES | ALTANA PHARMA AG (DE) | 2013-03-28 | — | — | US | claimed |
| US-8399505-B2 | Sulfonylpyrroles | 4SC AG (DE) | 2013-03-19 | — | — | US | claimed |
| US-7842820-B2 | Sulfonylpyrroles | 4SC AG (DE) | 2010-11-30 | — | — | US | claimed |
| US-20100261761-A1 | Novel Sulfonylpyrroles | MAIER THOMAS | 2010-10-14 | — | — | US | claimed |
| US-20070184979-A1 | Novel sulfonylpyrroles | ALTANA PHARMA AG (DE) | 2007-08-09 | — | — | US | claimed |
| EP-1725528-A2 | SULPHONYLPYRROLES AS HDAC INHIBITORS | Altana Pharma AG (DE) | 2006-11-29 | — | — | EP | claimed |
| WO-2005087724-A2 | SULPHONYLPYRROLES AS HDAC INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-22 | — | — | WO | claimed |
| WO-2019043176-A2 | HDAC INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY | 4SC AG (DE) | 2019-03-07 | — | — | WO | disclosed |
| US-8969401-B2 | Sulfonylpyrroles | 4SC AG (DE) | 2015-03-03 | — | — | US | disclosed |
| EP-1725528-B1 | SULPHONYLPYRROLES AS HDAC INHIBITORS | 4SC AG (DE) | 2013-05-29 | — | — | EP | disclosed |
| EP-1928826-B1 | SULPHONYLPYRROLE HYDROCHLORIDE SALTS AS HISTONE DEACETYLASES INHIBITORS | 4SC AG (DE) | 2013-04-24 | — | — | EP | disclosed |
| US-20130079347-A1 | NOVEL SULFONYLPYRROLES | ALTANA PHARMA AG (DE) | 2013-03-28 | — | — | US | disclosed |
| EP-1928826-A1 | SULPHONYLPYRROLE HYDROCHLORIDE SALTS AS HISTONE DEACETYLASES INHIBITORS | Nycomed GmbH (DE) | 2008-06-11 | — | — | EP | disclosed |
| US-20070184979-A1 | Novel sulfonylpyrroles | ALTANA PHARMA AG (DE) | 2007-08-09 | — | — | US | disclosed |
| WO-2007039403-A1 | SULPHONYLPYRROLE HYDROCHLORIDE SALTS AS HISTONE DEACETYLASES INHIBITORS | NYCOMED GMBH (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039404-A1 | NOVEL SULPHONYLPYRROLES AS INHIBITORS OF HDAC S NOVEL SULPHONYLPYRROLES | NYCOMED GMBH (DE) | 2007-04-12 | — | — | WO | disclosed |
| EP-1725528-A2 | SULPHONYLPYRROLES AS HDAC INHIBITORS | Altana Pharma AG (DE) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005087724-A2 | SULPHONYLPYRROLES AS HDAC INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070184979-A1 | Novel sulfonylpyrroles | HDAC1, HDAC4, HDAC3 | HDAC1 1/4885HDAC6 8/4885HDAC3 3/4885 |
| US-20100261761-A1 | Novel Sulfonylpyrroles | HDAC3, HDAC1, HDAC2 | HDAC1 2/4885HDAC6 7/4885HDAC3 1/4885 |
| US-20130079347-A1 | NOVEL SULFONYLPYRROLES | HDAC3, HDAC1, HDAC2 | HDAC1 2/4885HDAC6 7/4885HDAC3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.